GLP-1s Were Only the Beginning: The Growing Role of Pharmacists in Peptide Medicine

Health systems are rapidly entering a new era of chronic peptide therapy. What began largely as diabetes management has quickly expanded into obesity medicine, cardiovascular risk reduction, metabolic liver disease, pediatric obesity care, menopause care, rheumatology, and broader metabolic health management. Semaglutide (Wegovy, Ozempic, Rybelsus; Novo Nordisk), tirzepatide (Mounjaro, Zepbound; Eli Lilly), and emerging incretin-based therapies are reshaping how clinicians approach chronic disease.^1-4 But as prescribing accelerates across primary care, endocrinology, cardiology, bariatrics, rheumatology, pediatrics, menopause clinics, and wellness practices, long-term support infrastructure has not evolved at the same pace.

Patients are increasingly remaining on these therapies for years rather than months. At the same time, health care professionals are learning more about long-term nutritional considerations, body composition changes, oral health implications, medication interactions, perioperative management, and compounded peptide safety concerns associated with chronic therapy.

The patient population itself is also expanding. Glucagon-like peptide-1 (GLP-1) therapies are now being used across pediatric, adult, and geriatric populations, often in patients with multiple comorbidities, polypharmacy, and complex nutritional needs.

At the same time, patients are increasingly exposed to peptide-focused wellness clinics, compounded peptide marketing, social media-driven health information, and supplement-based approaches aimed at optimizing weight loss, muscle preservation, recovery, and longevity. Although GLP-1 receptor agonists remain among the most rigorously studied peptide therapies in medicine, many emerging peptides being promoted for body composition, anti-aging, or performance enhancement lack standardized dosing guidance and robust long-term human safety data.⁵ Investigational approaches focused on preservation of lean body mass during weight reduction are also beginning to emerge alongside incretin-based therapies, reflecting a broader shift from weight loss alone toward long-term body composition management.⁶

The future challenge may involve far more than medication titration alone. It may require healthcare systems capable of supporting long-term peptide management across increasingly complex patient populations.

Why Pharmacists May Be Uniquely Positioned

In many settings, pharmacists are among the first health care professionals patients contact when complications or tolerability concerns emerge. As both a board-certified clinical pharmacist and former intensive care clinical pharmacist within the Veterans Affairs health care system for more than a decade, I observed firsthand how medication-related complications can increase health care utilization when adverse drug reactions are not identified early.

Critical care literature has repeatedly demonstrated that integrating clinical pharmacists into multidisciplinary teams improves patient outcomes and reduces preventable adverse drug events.⁷ A similar prevention-focused framework may apply to obesity and metabolic medicine.

Clinical pharmacist-led GLP-1 programs are already emerging in ambulatory care settings. As peptide therapies continue expanding across medicine, pharmacists may play a larger role in helping patients and multidisciplinary health care teams navigate the broader nutritional, metabolic, and safety implications associated with chronic peptide use.

Pharmacists are uniquely trained to evaluate pharmacology, dose-response relationships, drug interactions, nutrition, hydration, supplement use, and medication tolerability simultaneously. In many cases, pharmacists may recognize when symptoms reflect excessive dose escalation, medication intolerance, nutritional compromise, or supplement-drug interactions before complications become severe.

This creates a different clinical lens than symptom-based management alone. Pharmacists are trained to evaluate where a medication acts within the body, how pharmacokinetics and pharmacodynamics influence tolerability, and when dose adjustment may prevent escalation of symptoms. Rather than simply adding additional therapies to manage adverse effects, pharmacists may help identify when slower titration, temporary dose reduction, nutritional intervention, or supportive care strategies are more appropriate.

As patients increasingly seek herbal therapies and supplements to manage symptoms such as nausea, constipation, fatigue, hair loss, reduced oral intake, or muscle loss, integrative medicine education may also become increasingly important within GLP-1 clinics. Pharmacists remain uniquely positioned to identify supplement drug interactions, evaluate evidence quality, and help educate both patients and health care professionals regarding safer supportive care strategies.

Preventing Complications in Long-Term Peptide Care

Oral health may represent an overlooked aspect of GLP-1 therapy. Patients commonly report dry mouth, altered taste, reflux, and reduced thirst. Emerging literature suggests GLP-1 receptor agonists may affect salivary gland signaling and contribute to xerostomia, although prospective clinical data remain limited.⁸ Reduced salivary flow may increase risk for dental caries, enamel erosion, oral discomfort, and reflux-related damage, yet oral health counseling is rarely incorporated into obesity medicine workflows.

Delayed gastric emptying associated with GLP-1 therapy may also contribute to perioperative aspiration concerns. Older adults may present additional complexity during therapy, particularly those with polypharmacy and multiple comorbidities.

Eye health monitoring may also become increasingly important during GLP-1 therapy. Rapid glycemic improvement may transiently worsen diabetic retinopathy in susceptible patients, particularly those with preexisting diabetic eye disease or rapid glucose lowering.⁹

The Need for Future Pharmacist Specialization

Health care systems are rapidly expanding peptide prescribing faster than long-term support models are evolving around these therapies. Yet currently, no board-recognized peptide or metabolic medicine specialty exists within Board of Pharmacy Specialties certification pathways.

As medication regimens and chronic disease management become more complex, health care systems have historically responded through pharmacist specialization and advanced board certification pathways. Similar models previously emerged in oncology, ambulatory care, critical care, nutrition support, and infectious disease as therapies became increasingly specialized and multidisciplinary in nature.

As peptide therapeutics continue expanding across obesity medicine, metabolic disease, pediatrics, women’s health, geriatrics, wellness medicine, and longevity-focused care, future specialty pathways focused on peptide therapeutics and longitudinal metabolic management may eventually become necessary.

Highly trained pharmacist-led metabolic clinics may help improve patient education, multidisciplinary coordination, medication optimization, supplement-drug interaction management, and long-term monitoring surrounding peptide therapy. Advanced pharmacist training may also help pharmacists remain current on evolving clinical data, nutrition science, body composition management, emerging therapies, and integrative medicine strategies increasingly encountered in real-world patient care.

Future peptide-focused certification pathways and continuing education programs may help prepare pharmacists to serve as stronger clinical educators and multidisciplinary resources within this rapidly evolving therapeutic landscape.

Conclusion

Health care systems are entering a peptide era faster than long term care models are evolving around these therapies. As GLP-1s and emerging peptide treatments continue expanding across obesity medicine, cardiometabolic disease, pediatrics, women’s health, rheumatology, and geriatric care, clinical pharmacists may play an increasingly important role in improving medication optimization, patient education, multidisciplinary coordination, and long-term metabolic management.

The future challenge may involve not simply expanding access to peptide therapies but building health care infrastructure capable of safely supporting patients receiving them long-term.

REFERENCES

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038

3. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640

4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563

5. Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. doi:10.1007/s40279-026-02437-0

6. Mastaitis JW, Gomez D, Raya JG, et al. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates. Nat Commun. 2025;16(1):4377. doi:10.1038/s41467-025-594858-9

7. Lee H, Ryu K, Sohn Y, Kim J, Suh GY, Kim E. Impact on patient outcomes of pharmacist participation in multidisciplinary critical care teams: a systematic review and meta-analysis. Crit Care Med. 2019;47(9):1243-1250. doi:10.1097/CCM.00000000003830

8. Barać M, Roganović J. GLP-1 receptor signaling and oral dysfunction: a narrative review on the mechanistic basis of semaglutide-related oral adverse effects. Biology (Basel). 2025;14(12):1650. doi:10.3390/biology14121650

9. Wegovy [prescribing information]. Novo Nordisk; May 2026. Accessed May 26, 2026. https://www.novo-pi.com/wegovy.pdf